Christian Maare

consultant oncologist, MD, ph.d., Head and Neck Section

Denmark

Research Interests

Explore related searches

Professors in Medical Imaging

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Christian Maare is a Consultant Oncologist and Head of the Head and Neck Section at Herlev Hospital Onkologisk Afdeling in Denmark. His research focuses on head and neck squamous cell carcinoma, evidenced by his recent publications on topics such as the quality assurance of radiotherapy, the efficacy of pembrolizumab treatment, and the prognostic impact of HPV-related markers. Dr. Maare is actively involved in studies under the DAHANCA initiative, contributing to advancements in cancer treatment and management.

Articles (12)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (10)

Anita Gothelf

Copenhagen University Hospital

DENMARK

View details

Jan Alsner

Aarhus University

DENMARK

View details

Jacob Kinggaard Lilja-Fischer

Aarhus University

DENMARK

View details

Christian Rønn Hansen

Odense University Hospital

DENMARK

View details

Eva Samsøe

Chief Medical Physicist, PhD

Zealand University Hospital Køge

DENMARK

View details

Cai Grau

Aarhus University

DENMARK

View details

Weronika Maria Szejniuk

Aalborg University

DENMARK

View details

Magnus Stougaard

Aarhus University

DENMARK

View details

Brita Singers Sørensen

Aarhus University

DENMARK

View details

Trine Tramm

Associate Professor, Consultant Pathologist

Aarhus University

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christian Maare

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study

Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial

Subsite variation of HPV-related p16-expression in oropharynx cancer: Incidence and prognostic impact in a population-based DAHANCA cohort 1986–2020

DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck

Management of head and neck cancer of unknown primary: A phase IV study by DAHANCA

Interobserver variation in organs at risk contouring in head and neck cancer according to the DAHANCA guidelines

High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma – A DAHANCA 19 study

Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – A DAHANCA 19 study

HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study

Split-filter dual energy computed tomography radiotherapy: From calibration to image guidance

Co-registration of radiotherapy planning and recurrence scans with different imaging modalities in head and neck cancer

Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma

Collaborators (10)

Anita Gothelf

Jan Alsner

Jacob Kinggaard Lilja-Fischer

Christian Rønn Hansen

Eva Samsøe

Cai Grau

Weronika Maria Szejniuk

Magnus Stougaard

Brita Singers Sørensen

Trine Tramm

Make your next move.